Exacerbation of myasthenia gravis after zoledronic acid and denosumab: a novel clinical observation with therapeutic implications
Stefania Canneva, Anna De Giovanni, Felicita Pagella, Carlo Trompetto, Marina Grandis, Laura Mori · 2026
Read Exacerbation of myasthenia gravis after zoledronic acid and denosumab: a novel clinical observation with therapeutic implications by Stefania Canneva, Anna De Giovanni, Felicita Pagella, Carlo Trompetto, Marina Grandis, Laura Mori (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13520302.txt.
Description
Stefania Canneva and colleagues describe in 2026 a single patient whose stable myasthenia gravis flared after two different bone-strengthening treatments. Myasthenia gravis causes fluctuating muscle weakness, while long-term steroid use for the condition can thin bones and prompt bone treatment.
The patient was a 78-year-old woman with long-standing, stable disease. Weakness worsened after an infusion of zoledronic acid and again after one dose of denosumab, and each flare needed a temporary rise in steroid dose. Bone drugs were then stopped, while vitamin D continued. The authors note that a denosumab-linked flare had not been reported before, so clinicians may want closer watch after dosing.
Catalog record
| CREATOR | Stefania Canneva, Anna De Giovanni, Felicita Pagella, Carlo Trompetto, Marina Grandis, Laura Mori |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 11198 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |